Cryoport (NASDAQ:CYRX – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) are both small-cap transportation companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.
Volatility and Risk
Cryoport has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Insider and Institutional Ownership
92.9% of Cryoport shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 10.1% of Cryoport shares are held by company insiders. Comparatively, 8.0% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cryoport | $225.61 million | 1.52 | -$99.59 million | ($2.47) | -2.83 |
| Cyclacel Pharmaceuticals | $420,000.00 | 4.10 | -$22.56 million | ($16.57) | -0.05 |
Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cryoport and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cryoport | -76.48% | -15.55% | -7.41% |
| Cyclacel Pharmaceuticals | -21,963.75% | -1,901.11% | -197.11% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Cryoport and Cyclacel Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cryoport | 0 | 3 | 2 | 0 | 2.40 |
| Cyclacel Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
Cryoport currently has a consensus target price of $11.60, indicating a potential upside of 66.19%. Cyclacel Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 1,275.00%. Given Cyclacel Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Cryoport.
Summary
Cryoport beats Cyclacel Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Cryoport
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.
